Evidence map›Paper›PMID 40183079›Full record

ArticleFrontiers in pharmacology2025

The interaction between a leflunomide-response methylation site (cg17330251) and variant (rs705379) on response to leflunomide in patients with rheumatoid arthritis.

Feng Zhao, Yulan Chen, Haina Liu, Lei Jin, Xin Feng, Bingbing Dai, Meng Chen, Qiao Wang, Yuxin Yao, Ruobing Liao and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Feng ZhaoDepartment of Clinical Epidemiology and Evidence-based Medicine, The First Hospital, China Medical University, Shenyang, China.
Yulan ChenDepartment of Clinical Epidemiology and Evidence-based Medicine, The First Hospital, China Medical University, Shenyang, China.
Haina LiuDepartment of Rheumatology, The First Hospital, China Medical University, Shenyang, China.
Lei JinDepartment of Rheumatology, ShengJing Hospital Affiliated of China Medical University, Shenyang, China.
Xin FengDepartment of Rheumatology, First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.
Bingbing DaiDepartment of Rheumatology and Immunology, Dalian Municipal Central Hospital, Dalian, China.
Meng ChenDepartment of Clinical Epidemiology and Evidence-based Medicine, The First Hospital, China Medical University, Shenyang, China.
Qiao WangDepartment of Clinical Epidemiology and Evidence-based Medicine, The First Hospital, China Medical University, Shenyang, China.
Yuxin YaoDepartment of Clinical Epidemiology and Evidence-based Medicine, The First Hospital, China Medical University, Shenyang, China.
Ruobing LiaoDepartment of Clinical Epidemiology and Evidence-based Medicine, The First Hospital, China Medical University, Shenyang, China.
Junyi ZhaoDepartment of Clinical Epidemiology and Evidence-based Medicine, The First Hospital, China Medical University, Shenyang, China.
Bingjia QuDepartment of Clinical Epidemiology and Evidence-based Medicine, The First Hospital, China Medical University, Shenyang, China.
Ying SongDepartment of Clinical Epidemiology and Evidence-based Medicine, The First Hospital, China Medical University, Shenyang, China.
Lingyu FuDepartment of Clinical Epidemiology and Evidence-based Medicine, The First Hospital, China Medical University, Shenyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: This research aims to reveal the mechanisms of the effect of the Paraoxonase 1 ( Methods: A total of 240 RA patients enrolled were categorized into the good response group and the non-response group according to the difference in DAS28 scores between baseline and 6 months after LEF administration. The identified LEF-response cytosine-phosphate-guanines (CpGs) island (cg17330251) and its internal SNPs (rs705379, etc.) located at the Results: A total of 12 CpG sites at cg17330251 could be identified in our RA patients. There were significant difference between the responders and non-responders in nine CpG sites: cg17330251_2, cg17330251_3, cg17330251_4, cg17330251_6, cg17330251_7, cg17330251_8, cg17330251_9, cg17330251_10, cg17330251_12, [OR (95CI%) = 0.492 (0.250, 0.969), 0.478 (0.243, 0.940), 0.492 (0.250, 0.969), 0.461 (0.234, 0.907), 0.492 (0.250, 0.969), 0.437 (0.225, 0.849), 0.478 (0.243, 0.941), 0.421 (0.212, 0.836), 0.424 (0.213, 0.843), Conclusion: The RA patients with SNP-rs705379-CC, the low methylation level of

Indexed as

DNA methylation4leflunomidePON1rheumatoid arthritissingle nucleotide polymorphism

Identifiers

PMID40183079
PMCPMC11965123

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.